Changwei Peng

8PUBLICATIONS
49CO-AUTHORS
Predictive and prognostic markersReinforcement learningApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 13, 2025
Modeling lymph node metastases in vivo.

Rodrigo J Gonzalez, Changwei Peng, Ulrich H von Andrian

|Jun 28, 2024
Circulating KLRG1+ long-lived effector memory T cells retain the flexibility to become tissue resident.

Erin D Lucas, Matthew A Huggins, Changwei Peng

|Oct 19, 2022
Responsiveness to interleukin-15 therapy is shared between tissue-resident and circulating memory CD8+ T cell subsets.

Nicholas N Jarjour, Kelsey M Wanhainen, Changwei Peng

|May 19, 2022
P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Kelsey M Wanhainen, Changwei Peng, Maggie H Zhou

|Mar 10, 2022
The Extracellular ATP Receptor P2RX7 Imprints a Promemory Transcriptional Signature in Effector CD8+ T Cells.

Trupti Vardam-Kaur, Sarah van Dijk, Changwei Peng

|Oct 22, 2021
Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytes.

Maximilien Evrard, Erica Wynne-Jones, Changwei Peng

Pageof 2